...
首页> 外文期刊>Journal of Medicinal Chemistry >2,7-Dioxo-2,3,4,5,6,7-hexahydro-1H-benzo(h)(1,4)diazonine as a new template for the design of CCK(2) receptor antagonists.
【24h】

2,7-Dioxo-2,3,4,5,6,7-hexahydro-1H-benzo(h)(1,4)diazonine as a new template for the design of CCK(2) receptor antagonists.

机译:2,7-Dioxo-2,3,4,5,6,7-六氢-1H-苯并(h)(1,4)重氮作为设计CCK(2)受体拮抗剂的新模板。

获取原文
获取原文并翻译 | 示例

摘要

A novel series of nonpeptide CCK(2) receptor antagonists has been prepared, in which 2,7-dioxo-2,3,4,5,6,7-hexahydro-1H-benzo[h][1, 4]diazonine (5) was used as a chemical template. This uncommon ring system was obtained in a highly substituted form and in high yield by ozonolysis of the enamine bond of 1,2,3,4-tetrahydro-9H-pyrido[3, 4-b]indole derivatives (4), in which the configuration of the substituents was established stereoselectively via the Pictet-Spengler reaction. Further structural manipulation was guided by molecular modeling through comparison of fieldpoint-based structures of candidate compounds with a selected low-energy conformation of the representative CCK(2) receptor antagonist 5-[[[(1S)-[[(3, 5-dicarboxyphenyl)amino]carbonyl]-2-phenylethyl]amino]carbonyl]-6- [[( 1-adamantylmethyl)amino]carbonyl]indole (JB93182 (3)). By this approach compounds such as (3R, 5S)-4-acetyl-3-(1-adamantyl)methyl-1-(2-chlorobenzyl)-5-carboxymet hyl aminocarbonyl-2,7-dioxo-2,3,4,5,6,7-hexahydro-1H-benzo[h][1, 4]diazonine (32) were prepared. Compound 32 behaved as a competitive CCK(2) receptor antagonist in vitro as judged by its inhibition of pentagastrin-stimulated acid secretion in an isolated, lumen-perfused, immature rat stomach assay (pK(B) = 6.74 +/- 0.27) and by its displacement of [(125)I]CCK-8S from CCK(2) sites in mouse cortical homogenates (pK(i) = 6.99 +/- 0.05). Compound 32 was 100-fold selective for CCK(2) over CCK(1) receptors based on the affinity estimate obtained in a guinea pig pancreas radioligand binding assay (pK(i) = 5.0).
机译:制备了一系列新型的非肽CCK(2)受体拮抗剂,其中2,7-二氧代-2,3,4,5,6,7-六氢-1H-苯并[h] [1,4]重氮( 5)用作化学模板。该不常见的环系统是通过对1,2,3,4-四氢-9H-吡啶并[3,4-b]吲哚衍生物(4)的烯胺键进行臭氧分解而以高取代形式和高收率获得的,其中取代基的构型通过Pictet-Spengler反应立体选择性地建立。通过分子建模,通过比较候选化合物与代表的CCK(2)受体拮抗剂5-[[[[(1S)-[[(3,5-二羧基苯基)氨基]羰基] -2-苯基乙基]氨基]羰基] -6-[[((1-金刚烷基甲基)氨基]羰基]吲哚(JB93182(3))。通过这种方法,诸如(3R,5S)-4-乙酰基-3-(1-金刚烷基)甲基-1-(2-氯苄基)-5-羧基甲基氨基羰基-2,7-二氧代-2,3,4的化合物制备了5,6,7-六氢-1H-苯并[h] [1,4]重氮(32)。化合物32在体外表现为竞争性CCK(2)受体拮抗剂,这是通过在单独的,未灌注管腔灌注的未成熟大鼠胃部测定法中抑制五肽胃泌素刺激的酸分泌来判断的(pK(B)= 6.74 +/- 0.27)和通过其从小鼠皮质匀浆中的CCK(2)位点[[125)I] CCK-8S的位移(pK(i)= 6.99 +/- 0.05)。基于在豚鼠胰腺放射性配体结合试验中获得的亲和力估计值,化合物32对CCK(2)的选择性比CCK(1)受体高100倍(pK(i)= 5.0)。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号